Summary
This technical report outlines the role of artificial intelligence (AI) in enhancing clinical trial strategies for drug developers. It discusses the imperative for quick decision-making in clinical trial execution to minimize drug development timelines and maximize market advantage. The report presents findings from a survey indicating that 45% of pharmaceutical companies have experienced longer trial durations over the past two years. It details how AI applications are expected to double in adoption by 2030, significantly contributing to healthcare market growth through cost savings. The document explains various AI-driven methodologies that improve trial design efficiency, streamline participant enrollment, and enable real-time decision-making. It also addresses challenges in AI adoption, including fragmented regulatory landscapes and a shortage of digital skills among healthcare professionals. The report concludes by emphasizing the need for innovative trial strategies to enhance success rates and reduce costs in drug development, highlighting the importance of partnerships and regional governance in implementing AI solutions.
